Results 61 to 70 of about 4,011 (178)

Long‐Term Treatment With Subcutaneous Treprostinil in Patients With Severe Inoperable Chronic Thromboembolic Pulmonary Hypertension in the Multimodal Therapy Era (Data From CTREPH Study Open Label Extension)

Pulmonary Circulation
The aim of the open label extension (OLE) of CTREPH study was to characterize multimodal treatment in patients with severe inoperable CTEPH, to describe long‐term subcutaneous (SC) treprostinil safety and tolerability, and to evaluate change in ...
Pavel Jansa, Roela Sadushi‐Kolici, Nika Skoro‐Sajer, Grzegorz Kopec, Iveta Simkova, Regina Steringer‐Mascherbauer, Barbara Salobir, Jaroslav Lindner, Irene M. Lang   +8 more
doaj   +1 more source

Angiotensin Converting Enzyme Inhibition and Mortality in Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH‐COPD)

Pulmonary Circulation, Volume 16, Issue 3, July 2026.
ABSTRACT In 567 PH‐COPD patients from the PVRI GoDeep Meta‐Registry, ACE inhibitor use was associated with improved survival only in severe PH (PVR > 5 WU), supporting prospective trials targeting this high‐risk subgroup.
Athiththan Yogeswaran, Meike Fünderich, Katharina Wendlandt, Jeffrey S. Annis, Evan Brittain, Christina A. Eichstaedt, Ekkehard Grünig, Hector R. Cajigas, Robert Frantz, Andrew J. Sweatt, Roham T. Zamanian, Friedrich Grimminger, Jochen Wilhelm, Hossein‐Ardeschir Ghofrani, Khodr Tello, Werner Seeger, PVRI GoDeep Consortium, Mauro Acquaro, Imad Al Ghouleh, James Anderson, Anastasia Anthi, Alexandra Arvanitaki, Aparna Balasubramanian, Felix Ballmann, Joan Albert Barbera, Harm Jan Bogaard, Hugh Buzacott, John Cannon, Demircan Ceren, Stephen Y. Chan, Alejandro Cruz Utrilla, Victoria Damonte, Eckart De Bie, Juliana De Luque Figueroa, Effrosyni Dima, Philipp Douschan, Nathan Dwyer, Diego Echazarreta, Jean Elwing, Pilar Escribano Subias, Kai Förster, Marlize Frauendorf, Stefano Ghio, George Giannakoulas, Lars Harbaum, Paul M. Hassoun, Melanie Heberling, Anne Hilgendorff, Luke Howard, Patrick Janetzko, Arun Jose, Ernesto Junaeda, Cihangir Kaymaz, David G. Kiely, Ingrid King, Hans Klose, Ziad Konswa, Grzegorz Kopec, Gabor Kovacs, Philipp Krieb, Keiichiro Kuronuma, Edmund Lau, Melanie Lavender, Allan Lawrie, Mona Lichtblau, Raphael W. Majeed, Kurt Marquardt, Hiromi Matsubara, Farhan Mubashir, Horst Olschewski, Mauricio Orozco‐Levi, Karen Osborn, Antonella Pepe, Joanna Pepke‐Zaba, Alba Ramirez‐Sarmiento, Timo Rosenbach, Stephan Rosenkranz, Hani Sabbour, Sandeep Sahay, Khaled Saleh, Laura Scelsi, Yuriy Sirenko, Siva Sivakumaran, Thenappan Thenappan, Ioan Tilea, Olena Torbas, Mark Toshner, Silvia Ulrich, Andrea Varga, Helen M. Whitford, Christoph B. Wiedenroth, Martin R. Wilkins, Paul G. Williams, Shaun Yo, Nayeli Zayas, Zhenguo Zhai, Zhu Zhang   +96 more
wiley   +1 more source

Clinical Utility of Treprostinil and Its Overall Place in the Treatment of Pulmonary Arterial Hypertension

, 2012
Pulmonary arterial hypertension (PAH) is a disease that leads to characteristic vascular wall remodeling and hemodynamic alterations. Consequently, this pulmonary vascular disease contributes to substantial morbidity and mortality in afflicted patients ...
Shireen Mirza, Raymond J. Foley
core   +1 more source

Short term effect of intravenous treprostinil in term and preterm infants with pulmonary hypertension

BMC Pediatrics
Background Pulmonary hypertension (PH) is a life-threatening condition in newborns. We aimed to assess the clinical and echocardiographic responses of term and preterm infants to treprostinil.
Yoo-Jin Kim, Seung Han Shin, Ee-Kyung Kim, Han-Suk Kim   +3 more
doaj   +1 more source

Real‐world use of inhaled treprostinil for lung disease‐pulmonary hypertension: A protocol for patient evaluation and prescribing

Pulmonary Circulation, 2022
Inhaled treprostinil was approved recently for interstitial lung disease‐pulmonary hypertension; however, efficacy in “real‐world” populations is not known.
Shelsey W. Johnson, Lauren Finlay, Stephen C. Mathai, Ronald H. Goldstein, Bradley A. Maron   +4 more
doaj   +1 more source

Activin Signaling Inhibitors in Pulmonary Hypertension: A State‐of‐the‐Art Review

Pulmonary Circulation, Volume 16, Issue 3, July 2026.
ABSTRACT Pulmonary arterial hypertension (PAH) is a disease of abnormal pulmonary vascular remodeling and vascular obliteration that results in right heart failure and death. PAH pathogenesis is strongly associated with mutations of the Transforming Growth Factor Beta (TGF‐β) superfamily signaling pathway, which has previously been challenging to ...
Sudarshan Rajagopal, Joseph Abueg, Kevin M. Hart, Edmund Lau, Eliana C. Martinez, Nicholas W. Morrell, Ioana R. Preston, Sandeep Sahay, Namita Sood, Paul B. Yu, Nayeli G. Zayas‐Hernández   +10 more
wiley   +1 more source

Noninvasive Gas Exchange Determinants of Exercise Hemodynamics in Non‐Severe Pulmonary Hypertension Associated With Interstitial Lung Disease

Pulmonary Circulation, Volume 16, Issue 3, July 2026.
ABSTRACT Level 3 cardiopulmonary exercise testing (CPET) can unmask the dynamic burden of pulmonary vascular disease (PVD), while submaximal exercise testing offers a simpler, noninvasive alternative. Emerging markers such as a gas‐exchange derived estimate of pulmonary vascular capacitance (GXCAP) and ventilatory efficiency (VE/VCO2) may reflect PVD ...
Chebly Dagher, Niala Moallem, Garrett Fiscus, Brett Carollo, Kristen Swanson, Harrison W. Farber, Raj Parikh   +6 more
wiley   +1 more source

Real‐World Comparison of Patients With PH‐ILD Initiating Inhaled Treprostinil Versus Patients Who Remain Untreated

Pulmonary Circulation
Pulmonary hypertension due to interstitial lung disease (PH‐ILD) is associated with high morbidity and mortality. Real‐world patients initiating inhaled treprostinil are not well‐characterized. This retrospective cohort study aimed to evaluate healthcare
Steven J. Cassady, Gautam V. Ramani, Benjamin Wu, Kellie Morland, Charles D. Burger   +4 more
doaj   +1 more source

Pediatric subcutaneous treprostinil site maintenance and pain control strategies from the Pediatric Pulmonary Hypertension Network

Pulmonary Circulation, 2021
Pulmonary arterial hypertension is a chronic, progressive, and life-threatening disease in children with diverse causes of pulmonary arterial hypertension.
Emma O. Jackson, Anna Brown, Julia McSweeney, Claire Parker   +3 more
doaj   +1 more source

Phenotypic Clustering of Idiopathic Pulmonary Arterial Hypertension: Insights Into Pulmonary Vascular and Cardiometabolic Co‐Morbidity Trajectories

Pulmonary Circulation, Volume 16, Issue 3, July 2026.
ABSTRACT Idiopathic pulmonary arterial hypertension (IPAH) exhibits significant clinical heterogeneity, necessitating a precision medicine approach. This study aimed to identify distinct IPAH phenotypes using machine learning‐based clustering and to evaluate their longitudinal therapeutic responses and long‐term survival.
Cihangir Kaymaz, Barkin Kultursay, Hacer Ceren Tokgoz, Seda Tanyeri, Cagdas Bulus, Berhan Keskin, Caglar Emre Cagliyan, Metehan Kibar, Can Erdem, Aziz Vezir, Ipek Akkus, Muhammet Bulut, Aykun Hakgor, Ibrahim Halil Tanboga, Nihal Ozdemir   +14 more
wiley   +1 more source